Uncategorized
Lucentis receives European approval to treat several choroidal neovascularization conditions
Novartis announced that the European Commission approved an additional indication for Lucentis to treat patients with visual impairments stemming from choroidal neovascularization due to causes other than neovascular age-related macular degeneration or secondary to pathologic myopia. According to a company press release, the approval is applicable to all 28 European member states and Liechtenstein, Norway and Iceland. Lucentis (ranibizumab) is the first retinal treatment approved for these conditions.